Old Web
English
Sign In
Acemap
>
authorDetail
>
Kimberley J. Campbell
Kimberley J. Campbell
Medicine
intermediate risk
Chemotherapy
Internal medicine
Myeloid
4
Papers
244
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Association of febrile neutropenia (FN) risk factors (RFs) with incident FN in U.S. commercial and Medicare advantage patients receiving intermediate-risk chemotherapy for non-myeloid cancers between 2009 and 2019.
2021
Journal of Clinical Oncology
Edward C. Li
Elizabeth J. Bell
Kimberley J. Campbell
Lincy S. Lal
Jesse Peterson-Brandt
Gary H. Lyman
Show All
Source
Cite
Save
Citations (0)
Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.
2021
Journal of Clinical Oncology
Edward C. Li
Kimberley J. Campbell
Bridgette Kanz Schroader
David Campbell
Stephen Chaplin
Gary H. Lyman
Show All
Source
Cite
Save
Citations (0)
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
2020
Journal of Clinical Oncology
Edward C. Li
Dylan Mezzio
Kimberley J. Campbell
Andrew Spargo
Gary H. Lyman
Show All
Source
Cite
Save
Citations (2)
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
2005
Journal of Clinical Oncology
David W. Nyman
Kimberley J. Campbell
Evan M. Hersh
Kristen Long
Kelly Richardson
Vuong Trieu
Neil Desai
Michael J. Hawkins
Daniel D. Von Hoff
Show All
Source
Cite
Save
Citations (242)
1